Jeito
  • About
  • The team
  • Our portfolio
  • ESG & Impact
  • Newsroom
  • Contact
  • English
    • Français
    • English
Select Page

Jeito Capital participates in a $95 Million financing for HI-Bio™, a US-based clinical-stage biopharma company developing targeted therapies for patients with severe immune-mediated diseases

by Manon FRACHON | 4 Jan Thu | English

One year after its first investment, this new significant participation in HI-Bio™’s Series B financing, alongside major international investors, demonstrates the value creation already achieved by the company and underlines its attractiveness With this 6th...

Jeito Capital portfolio company Advesya emerges from stealth mode with the potential to become a leader in the treatment of hematological malignancies and other tumor treatments

by Manon FRACHON | 3 Jan Wed | English

Paris, France, 3 January 2024 – Jeito Capital (“Jeito”), a global leading independent private equity fund dedicated to biopharma, is pleased to announce the un-stealthing [1] of its portfolio company Advesya, a pioneering biopharma company for...

Jeito Capital announces appointment of new Partner Investor Ksenija Pavletic

by Manon FRACHON | 3 Jan Wed | English

Paris, France, 3 January 2024 – Jeito Capital (“Jeito”), a global leading independent private equity fund dedicated to biopharma, is pleased to announce the promotion of Ksenija Pavletic to Partner Investor. As part of the Jeito founding team with...

Jeito Capital creates a community of leading international Special Advisors to complement its extensive sets of skills and further extend its support to portfolio companies

by Manon FRACHON | 29 Nov Wed | English

Paris, France, November 29th 2023 – Jeito Capital (“Jeito”), a leading global investment company dedicated to biopharmaceuticals in Europe, is proud to announce the formation of its Special Advisors community composed of leading academic and industry experts...

Jeito Capital leads €75 million Series B Financing in NMD Pharma, a Danish company, to develop breakthrough treatments for patients with severe neuromuscular diseases

by Manon FRACHON | 15 Nov Wed | English

Jeito Capital’s second round of funding will support NMD Pharma in becoming a leading, global, clinical-stage company, with a strong pipeline of breakthrough therapies for patients suffering from severe neuromuscular disorders. This funding round will also contribute...
« Older Entries
Next Entries »

Recent Posts

  • Jeito Capital promotes Ksenija Pavletic to General Partner
  • Jeito Capital announces significant participation in oversubscribed $213M Series D financing for Odyssey Therapeutics to advance clinical pipeline addressing autoimmune diseases with high unmet needs
  • Jeito Capital appoints Pascal Touchon as Operating Partner
  • Jeito Capital Leads a USD 65 million Financing in ReproNovo to Develop Transformational Treatments in Reproductive Medicine and Women’s Health
  • Jeito Capital leads EUR 132 million oversubscribed Series B financing in Azafaros to advance Phase 3 clinical programs of innovative therapies in rare inherited neuro-metabolic disorders

Recent Comments

    Mentions et autres liens
    We use cookies to provide you with the best possible website experience by
    offering you tailored content and for statistical purposes. You can modify your
    choices at any time. For more information, please consult our cookie policy.
    Cookie settingsAccept allReject all
    Manage consent

    Privacy Overview

    This website uses cookies to improve your experience while browsing the site. Among these, cookies that are categorized as necessary are stored on your browser as they are essential for the basic functionality of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will only be stored in your browser with your consent. You also have the option to decline these cookies. However, disabling some of these cookies may affect your browsing experience.
    Necessary
    Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
    SAVE & ACCEPT